Connection

Konstantinos Syrigos to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Konstantinos Syrigos has written about Antibodies, Monoclonal, Humanized.
Konstantinos Syrigos
Connection Strength
0.009
Antibodies, Monoclonal, Humanized
  1. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 2017 10; 112:126-133.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.